TABLE 2.

Effects on hyperphagia and social behaviour of total group

Items investigated	After 12 weeks of oxytocin			After 12 weeks of placebo			P *
	Median		IQR	Median		IQR
Oxytocin study questionnaire b
Total score	1.0		(−5.5 to 11.0)	‐2.0		(−8.5 to 5.5)	0.20
	Better	Same	Worse	Better	Same	Worse
Total score	13	3	9	8	3	14	0.30
Happiness	10	15	0	5	19	1	0.27
Anxious	6	17	2	1	22	2	0.06
Food seeking behaviour	5	18	2	0	21	4	0.06
Dykens change in hyperphagia b
Total score	0.0		(−1.0 to 3.0)	0.0		(−6.0 to 0.0)	0.06
	Better	Same	Worse	Better	Same
Total score	8	9	8	3	11	11	0.18
Improvement social behaviour	14			6			0.12
Improvement eating behaviour	7			1			0.07
RBS‐R total score a	11.0		(5.5‐16.5)	14.0		(5.0‐22.5)	0.20
SRS‐P total score a	68.0		(55.0‐80.5)	68.0		(50.0‐78.5)	0.52
Measurements
∆weight (kg)	1.0		(0.4‐2.1)	1.0		(0.6‐1.4)	0.70
∆BMI (kg/m2)	0.3		(−0.3 to 0.7)	0.3		(−0.1 to 0.6)	0.65
∆fat percentage	0.3		(−1.0 to 1.4)	0.3		(−0.9 to 1.7)	0.59
∆lean body mass (gram)	552.0		(115.8‐913.0)	357.5		(−315.5 to 869.5)	0.21
Safety
Systolic blood pressure	105.0		(100.0‐112.0)	108.0		(97.8‐116.3)	0.55
Diastolic blood pressure	66.0		(61.0‐69.0)	65.0		(57.0‐76.5)	0.87
Fasting glucose	5.0		(4.6‐5.1)	4.8		(4.5‐5.1)	0.08
Fasting insulin	58.0		(41.0‐101.8)	64.5		(26.0‐92.0)	0.90

Data expressed in median (IQR) unless otherwise specified;

^ba positive score indicates improvement.

^aa higher score indicates more problems in behaviour.

^* P‐value between oxytocin and placebo phase. P‐value for variables expressed in better, same, worse, is the P‐value for better versus same and worse.